Los Angeles Capital Management
SLDB icon

Los Angeles Capital Management’s Solid Biosciences SLDB Stock Holding History

Los Angeles Capital Management’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Sell
36,920
-500
-1% -$3.79K ﹤0.01% 996
2026
Q1 		$269K Buy
+37,420
New +$240K ﹤0.01% 1061
2025
Q1 		– Sell
-42,989
Closed -$172K – 1212
2024
Q4 		$172K Buy
42,989
+930
+2% +$5.11K ﹤0.01% 1070
2024
Q3 		$293K Buy
+42,059
New +$341K ﹤0.01% 1019

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Los Angeles Capital Management's SLDB Position: Q2 2026 in Review

Los Angeles Capital Management reduced its Solid Biosciences (SLDB) stake by 1.3% in Q2 2026, selling an estimated $3.79K and leaving 36,920 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Los Angeles Capital Management first reported a position in SLDB in Q3 2024 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • Los Angeles Capital Management held 36,920 shares of Solid Biosciences worth $369K as of Q2 2026.
  • Los Angeles Capital Management sold 500 Solid Biosciences shares in Q2 2026, an estimated $3.79K.
  • Solid Biosciences made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #996 holding.
  • Los Angeles Capital Management first reported a position in Solid Biosciences in Q3 2024 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.